{"id":"W2988183880","doi":"10.1182/blood-2019-123949","title":"Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Obinutuzumab; Medicine; CD20; Refractory (planetary science); Lymphoma; Oncology; Phases of clinical research; Rituximab; Internal medicine; Clinical trial; Cancer research; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001743594,0.0004761628,0.001197389,0.0002344941,0.0001161902,0.0000860596,0.0001741833,0.0004202121,0.0003399439],"category_scores_gemma":[0.0002524285,0.0003507831,0.0001340392,0.0003585164,0.0002773377,0.0002272632,0.0001654014,0.0008209709,0.00001449596],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002562526,"about_ca_system_score_gemma":0.0010463,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008123331,"about_ca_topic_score_gemma":0.0001601272,"domain_scores_codex":[0.9957666,0.000637087,0.0009441997,0.001282282,0.0007091835,0.0006605863],"domain_scores_gemma":[0.9966484,0.001607182,0.0003607992,0.0008771428,0.0001090287,0.0003975021],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.803779,0.01069326,0.002429284,0.0001438017,0.0004402418,0.0007318343,0.00136602,0.000002594957,0.1019811,0.000001726688,0.0002744532,0.07815664],"study_design_scores_gemma":[0.8849112,0.05138073,0.02887469,0.0005232602,0.0003020825,0.0001030739,0.0002588427,0.001958229,0.02562959,0.00001164229,0.005446321,0.0006003303],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922467,0.001088251,0.000009837224,0.0002059155,0.0003870509,0.004624959,0.0002037707,0.0000852047,0.001148337],"genre_scores_gemma":[0.9933962,0.001337969,0.0005504822,0.00009694885,0.0005358173,0.00008955061,0.0001643983,0.00009643888,0.003732243],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08113221,"threshold_uncertainty_score":0.9998944,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03937115457596355,"score_gpt":0.3341516338312315,"score_spread":0.2947804792552679,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}